References
- DouganMDranoffGImmune therapy for cancerAnnu Rev Immunol2009278311719007331
- RaderRAFDA Biopharmaceutical Product Approvals and Trends in 2012Westborough, MABioProcess International2011
- JackischCMullerVMaintzCHellSAtasevenBSubcutaneous administration of monoclonal antibodies in oncologyGeburtshilfe Frauenheilkd201474434334925076790
- KlingJHighly Concentrated Protein FormulationsWestborough, MABioProcess International2014
- LevequeDSubcutaneous administration of anticancer agentsAnticancer Res20143441579158624692685
- IsmaelGHeggRMuehlbauerSSubcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trialLancet Oncol201213986987822884505
- McCormackPLOmalizumab: a review of its use in patients with chronic spontaneous urticariaDrugs201474141693169925217402
- BorahBJHuangXZarotskyVGlobeDTrends in RA patients’ adherence to subcutaneous anti-TNF therapies and costsCurr Med Res Opin20092561365137719425902
- KhraishiMMExperience with subcutaneous abatacept for rheumatoid arthritis: an update for cliniciansTher Adv Musculoskelet Dis20146515916825342995
- KivitzACohenSDowdJEClinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trialClin Ther200628101619162917157117
- ScottLJEtanercept: a review of its use in autoimmune inflammatory diseasesDrugs201474121379141025034360
- SohnWSimiensMAJaegerKHuttonSJangGThe pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic reviewBr J Clin Pharmacol201478347748724548274
- MelicharBStudentovaHKalabovaHVitaskovaDRole of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancerImmunotherapy20146781181925290414
- PivotXGligorovJMullerVPatients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer studyAnn Oncol201425101979198725070545
- JezekJRidesMDerhamBViscosity of concentrated therapeutic protein compositionsAdv Drug Deliv Rev201163131107111722014592
- LiuJNguyenMDAndyaJDShireSJReversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solutionJ Pharm Sci20059491928194016052543
- NarasimhanCMachHShameemMHigh-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspectiveTher Deliv20123788990022900469
- SalujaAKaloniaDSNature and consequences of protein-protein interactions in high protein concentration solutionsInt J Pharm20083581–211518485634
- DiasCAbosaleemBCrispinoCGaoBShaywitzATolerability of high-volume subcutaneous injections of a viscous placebo buffer: a randomized, crossover study in healthy subjectsAAPS PharmSciTech Epub2015219
- US Army Medical DepartmentDistance Learning Course – Lesson 2: administer an intramuscular injection Available from: http://brooksidepress.org/Products/Administer_IM_SQ_and_ID_Injections/lesson_2_Section_1.htmAccessed September 8, 2015
- HeiseTNosekLDellwegSImpact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trialDiabetes Obes Metab2014161097197624720741
- JorgensenJTRomsingJRasmussenMMoller-SonnergaardJVangLMusaeusLPain assessment of subcutaneous injectionsAnn Pharmacother1996307–87297328826549
- CampbellWIPattersonCCQuantifying meaningful changes in painAnaesthesia19985321211259534632
- ToddKHClinical versus statistical significance in the assessment of pain reliefAnn Emerg Med19962744394418604855
- ChanHEffects of injection duration on site-pain intensity and bruising associated with subcutaneous heparinJ Adv Nurs200135688289211555036
- BerteauCSchwarzenbachFDonazzoloYEvaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteersPatient Prefer Adherence2010437938821049090
- PourghazneinTAzimiAVJafarabadiMAThe effect of injection duration and injection site on pain and bruising of subcutaneous injection of heparinJ Clin Nurs2014237–81105111323844561
- PivotXGligorovJMullerVPreference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyLancet Oncol2013141096297023965225
- European Medicines AgencyCHMP Assessment Report – Trastuzumab (Herceptin)London, UKEuropean Medicines Agency2013
- European Standard. BS EN 60601-2-24:1998Medical Electrical Equipment – Part 2: Particular Requirements for the Safety of Infusion Pumps and ControllersLondon, UKBritish Standards Institution1998
- BrazeauGACooperBSveticKASmithCLGuptaPCurrent perspectives on pain upon injection of drugsJ Pharm Sci19988766676779607942